Addition of lafutidine can improve disease activity and lead to better quality of life in refractory cholinergic urticaria unresponsive to histamine H1 antagonists
详细信息 查看全文
- 作者：Mayumi Hatakeyama ; Atsushi Fukunaga ; atsushi@med.kobe-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Ken Washio ; Kanako Ogura ; Yozo Yamada ; Tatsuya Horikawa ; Chikako Nishigori
- 关键词：CU ; cholinergic urticaria ; H1RA ; H1 receptor antagonists ; H2RA ; H2 receptor antagonists ; QoL ; quality of life ; DLQI-J ; Dermatology Life Quality Index
- 刊名：Journal of Dermatological Science
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：82
- 期：2
- 页码：137-139
- 全文大小：378 K
文摘
- •
Suitable treatment options except for H1RA are still lacking for severe refractory CU.
- •
Addition of lafutidine to H1RA treatment significantly improved urticarial symptoms in severe refractory CU.
- •
The DLQI score was markedly improved after the addition of lafutidine to H1RA treatment in severe refractory CU.
- •
No adverse events occurred after the addition of lafutidine in severe refractory CU.